Lmcg Investments LLC Acquires 10,110 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lmcg Investments LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 231.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,481 shares of the biopharmaceutical company's stock after purchasing an additional 10,110 shares during the period. Lmcg Investments LLC's holdings in Regeneron Pharmaceuticals were worth $9,184,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Gilman Hill Asset Management LLC boosted its position in Regeneron Pharmaceuticals by 1.9% in the first quarter. Gilman Hill Asset Management LLC now owns 5,303 shares of the biopharmaceutical company's stock valued at $3,363,000 after buying an additional 100 shares in the last quarter. Portside Wealth Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.6% in the 1st quarter. Portside Wealth Group LLC now owns 776 shares of the biopharmaceutical company's stock worth $492,000 after acquiring an additional 55 shares in the last quarter. Whipplewood Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3,220.0% in the 1st quarter. Whipplewood Advisors LLC now owns 166 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 161 shares in the last quarter. Merit Financial Group LLC grew its position in Regeneron Pharmaceuticals by 87.7% during the 1st quarter. Merit Financial Group LLC now owns 1,629 shares of the biopharmaceutical company's stock worth $1,033,000 after acquiring an additional 761 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $78,000. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on REGN shares. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday, March 31st. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $844.48.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $10.15 during midday trading on Friday, reaching $493.22. The stock had a trading volume of 1,497,861 shares, compared to its average volume of 858,657. The firm has a market cap of $53.25 billion, a PE ratio of 12.88, a P/E/G ratio of 2.34 and a beta of 0.31. The firm has a 50 day simple moving average of $572.23 and a 200-day simple moving average of $659.43. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $9.55 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.